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remain in the study if medical therapy failed and the end point of
angina was reached. Angina, unfortunately, is a subjective measure.
Irrespective of how “objective” the investigators were in determin-
ing the success or failure of antianginal therapy, the use of a
subjective end point may have inadvertently introduced bias into
the trial. It is difficult to draw proper conclusions from such a trial
when large crossover rates are allowed.
With respect to the European trial by Schofield et al. (2), the
number of sites with irreversible segments was adjusted for
baseline, and for repeated within-patient, between-site measures.
Therefore, to suggest that a “doubling” of fixed defects in the
medical therapy group implies enhanced perfusion in the TMR
group is inappropriate, especially because a subgroup analysis of
the same TMR patients showed no improvement in myocardial
perfusion with PET scanning (3).
To conclude, we believe that the reported benefits of TMR,
even out to five years, may be related to the placebo effect. It is the
most plausible mechanism of action, given the lack of concrete
evidence to the contrary. A properly powered, blinded, sham-
controlled surgical trial of TMR could certainly settle this issue. In
the absence of such a trial, however, more studies using new
perfusion imaging modalities must be conducted to elucidate the
true value of this technique.
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Mitochondrial Dysfunction in Heart Failure
I read with interest the report in the Journal by Scheubel et al. (1).
Although their conclusion that a deficit in the activity of respira-
tory chain complex I may not be due to generalized damage of
mitochondrial deoxyribonucleic acid (DNA) and gene expression
is most likely true, their statement in the discussion that “in an
experimental model of tachypacing-induced heart failure without
any drug treatment, a depression in the activities of all complexes
containing mitochondrially encoded subunits, including the mito-
chondrial adenosine triphosphatase, was described . . . , indicating
disturbed mitochondrial gene expression,” is inaccurate.
Marin-Garcia et al. (2) in their study of mitochondrial function
in pacing-induced cardiac failure reported that the activity levels of
complexes I and IV (complexes containing mitochondrially en-
coded subunits) were unchanged (normal) relative to controls.
Only one complex of the electron transport chain (complex III)
and adenosine triphosphate synthase (complex V) were affected
without changes in peptide content of specific mitochondrial
proteins. The reduced levels of complex III and complex V
activities did not appear to be due to generalized mitochondrial
damage, necrosis, or overall decreased levels of mitochondria as
gauged by unchanged levels of respiratory complex I, complex II
(nuclear encoded), complex IV, and citrate synthase (also nuclear
encoded). The levels of mitochondrial DNA deletions (7.4 kb)
were extremely low in comparison to wild-type genomes and
probably of no significance. Therefore, the investigators’ conclu-
sion that depression in the activity levels of the respiratory enzymes
and complex V in the pacing-induced cardiac failure indicate
disturbed mitochondrial gene expression is misguided. However, I
do agree that the protective role of drug treatment against
mitochondrial DNA damage remains to be proven.
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REPLY
We thank Dr. Marin-Garcia for the interest in our study (1). He
is right in stating that our citation of his study (2) “indicating
disturbed mitochondrial gene expression” is inaccurate. We regret
such inaccuracies, which must have occurred during several refor-
mulations of our text. The reasons for the reduced activities in
complex III and complex V in his tachypacing-induced failure
model (2) remain undetermined at present. However, we are happy
that Dr. Marin-Garcia agrees to our conclusion that a depressed
complex I activity in failing human myocardium may not be due to
generalized damage of mitochondrial deoxyribonucleic acid.
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